President Trump launched TrumpRx.gov on Thursday night, a new government platform that offers Americans significantly reduced prices on dozens of common, high-cost brand-name prescription medications through direct-to-consumer purchasing arrangements with pharmaceutical manufacturers.
The initiative leverages Most-Favored-Nation pricing agreements to deliver what the administration calls “massive, immediate savings” on prescription drugs. The platform debuted with 40 medications at reduced prices from five pharmaceutical manufacturers: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer — with Pfizer emerging as the largest initial participant, contributing over 30 medications to the platform.
Dramatic Price Reductions on Popular Medications
Perhaps most notable are the steep discounts on GLP-1 medications, which have surged in popularity for weight loss and diabetes management. Ozempic will now cost as little as $199 monthly, down from $1,028, while Wegovy’s injectable form drops from $1,349 to as low as $199. The pill version of Wegovy will be available for as little as $149, and Zepbound falls from $1,088 to an average of $346, with some dosages as low as $299 monthly, according to White House documents.
Fertility treatments, often not covered by insurance and prohibitively expensive for many Americans, also see significant price reductions. Gonal-F will be available for as low as $168 per pen, while Cetrotide drops dramatically from $316 to $22.50. Ovidrel falls from $251 to $84. These reductions could translate to average savings of more than $2,000 per IVF cycle, potentially lowering the overall cost of an IVF cycle by approximately 20 percent, as noted by health policy experts.
How does the platform actually work? Rather than functioning as a direct sales site, TrumpRx serves as a portal that directs patients to manufacturers’ websites for purchases. The Trump Administration stated it “will be onboarding additional companies that have Most-Favored-Nation agreements and is aggressively pursuing additional agreements to expand the platform — ultimately driving even greater savings for Americans on prescription drugs.”
Expanding Participation and Coverage
The roster of participating pharmaceutical companies is expected to grow. Beyond the initial five manufacturers, several major biopharmaceutical companies have entered into Most-Favored-Nation pricing agreements with the Trump administration, including Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline, Merck & Co, Novartis, and Sanofi, as reported by healthcare industry sources.
Still, questions remain about how the program will integrate with existing insurance coverage. The administration is calling on Congress to pass what it describes as the “Great Healthcare Plan,” which would codify the Most-Favored-Nation savings, lower insurance premiums, increase price transparency, and — crucially — enable coverage of TrumpRx.gov purchases under health insurance plans.
“For Americans who obtain their prescriptions through insurance, President Trump calls on Congress to swiftly pass his Great Healthcare Plan,” the White House announced. This “comprehensive reform would codify the savings from the Most-Favored-Nation initiative” and ensure “every American benefits from these historic reductions in drug costs.”
The launch represents a significant shift in how Americans might access prescription medications, potentially disrupting traditional pharmacy benefit managers and retail pharmacy chains if the program gains widespread adoption. Industry analysts are watching closely to see whether TrumpRx’s direct-to-consumer model will force broader price reductions across the pharmaceutical marketplace — or if its impact remains limited to those with the means to pay out-of-pocket for medications, even at reduced prices.
